Nano-Hydroxyapatite Bone Substitute Functionalized with Bone Active Molecules for Enhanced Cranial Bone Regeneration

ACS Appl Mater Interfaces. 2017 Mar 1;9(8):6816-6828. doi: 10.1021/acsami.6b14782. Epub 2017 Feb 20.

Abstract

The aim of this study was to synthesize and characterize a nano-hydroxyapatite (nHAP) and calcium sulfate bone substitute (NC) for cranioplasty. The NC was functionalized with low concentrations of bone morphogenetic protein-2 (BMP-2) and zoledronic acid (ZA) and characterized both in vitro and in vivo. In vitro studies included MTT, ALP assays, and fluorescent staining of Saos-2 (human osteoblasts) and MC3T3-E1 (murine preosteoblasts) cells cultured on NC. An in vivo study divided 20 male Wistar rats into four groups: control (defect only), NC, NC + ZA, and NC + ZA + rhBMP-2. The materials were implanted in an 8.5 mm critical size defect in the calvarium for 12 weeks. Micro-CT quantitative analysis was carried out in vivo at 8 weeks and ex vivo after 12 weeks. Mineralization was highest in the NC + ZA + rhBMP-2 group (13.0 ± 2.8 mm3) compared to the NC + ZA group (9.0 ± 3.2 mm3), NC group (6.4 ± 1.9 mm3), and control group (3.4 ± 1.0 mm3) after 12 weeks. Histological and spectroscopic analysis of the defect site provided a qualitative confirmation of neo-bone, which was in agreement with the micro-CT results. In conclusion, NC can be used as a carrier for bioactive molecules, and functionalization with rhBMP-2 and ZA in low doses enhances bone regeneration.

Keywords: bisphosphonates; bone morphogenetic proteins; cranial model; nano-hydroxyapatite; osteoinductive; solid state NMR.

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 2
  • Bone Regeneration*
  • Bone Substitutes
  • Durapatite
  • Humans
  • Male
  • Mice
  • Rats
  • Rats, Wistar
  • Recombinant Proteins
  • Skull
  • Transforming Growth Factor beta

Substances

  • Bone Morphogenetic Protein 2
  • Bone Substitutes
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • Durapatite